Anticorps Monoclonal anti-NeutraKine® IFN-beta

NeutraKine® IFN-beta Monoclonal Antibody for Neutralization, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain et plus (1)

Applications

Neutralization, ELISA, Cell treatment

Conjugaison

Non conjugué

Publications(3)

CloneNo.

2C6E5

N° de cat : 69013-1-Ig

Synonymes

NeutraKine® IFN beta, IFN beta, IFNB1, 2C6E5, IFN β1

---

Galerie de données de validation

• 

  Neutralization experiment of NeutraKine® IFN beta using 69013-1-Ig

  Recombinant IFN beta (Cat.NO. HZ-1298) inhibits TF-1 cell proliferation at dose dependent manner (blue curve, refer to bottom X-left Y). The activity of human IFN beta (10 ng/mL HZ-1298) is neutralized by mouse anti-human IFN beta monoclonal antibody 69013-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 5-20 ng/mL.

---

Neutralization

Informations sur le produit

69013-1-Ig cible NeutraKine® IFN-beta dans les applications de Neutralization, ELISA, Cell treatment et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain, souris
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: human Humankine IFN-beta protein HZ-1298
• Nom complet: IFN beta
• Symbole du gène: IFN beta1
• Identification du gène (NCBI): 3456
• Conjugaison: Non conjugué
• Forme: Lyophilized Powder
• Méthode de purification: Purification par protéine G
• Tampon de stockage: Sterile PBS
• Endotoxin: <0.1 EU/μg
• Reconstitution: This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
• Stability and Storage: Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Informations générales

Interferon beta (IFN beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.

This antibody can be used to neutralize the bioactivity of IFN beta.

Publications

Species	Application	Title
human	Neutralization	Nat Commun; Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association.; Authors - Lin Zhu
mouse	Neutralization	Cell Rep; Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis; Authors - Xinyue Ma
human	Cell treatment	Dev Cell; Glutamine binds HSC70 to transduce signals inhibiting IFN-β-mediated immunogenic cell death; Authors - Deyu Zhang

{{ptg:RelatedPrimaryAntibodies}}